Oculis raises CHF20M series B

Oculis ehf (Lausanne, Switzerland) raised CHF20 million ($20.3 million) in a series B round led by Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners. Existing investors Brunnur Ventures and Silfurberg also participated.

The round includes an initial CHF18 million tranche. Oculis expects the remaining CHF2 million in 1H19, pending milestones including submission of an IND for lead candidate OC-118 to treat diabetic macular edema. The therapy is a topical dexamethasone formulation developed using the company's Solubilizing Nanoparticle (SNP) technology platform...